[go: up one dir, main page]

AR062145A1 - Metoods y composiciones para aumentar el tropismo tisular de vectores adenovirales recombinantes - Google Patents

Metoods y composiciones para aumentar el tropismo tisular de vectores adenovirales recombinantes

Info

Publication number
AR062145A1
AR062145A1 ARP070103361A ARP070103361A AR062145A1 AR 062145 A1 AR062145 A1 AR 062145A1 AR P070103361 A ARP070103361 A AR P070103361A AR P070103361 A ARP070103361 A AR P070103361A AR 062145 A1 AR062145 A1 AR 062145A1
Authority
AR
Argentina
Prior art keywords
compositions
tropism
metoods
tissular
increase
Prior art date
Application number
ARP070103361A
Other languages
English (en)
Inventor
Michael Anthony Johnson
Jeffrey Michael Mahmond
Original Assignee
Csiro Livestock Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csiro Livestock Ind filed Critical Csiro Livestock Ind
Publication of AR062145A1 publication Critical patent/AR062145A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Geophysics And Detection Of Objects (AREA)

Abstract

Métodos que permiten la preparacion de vectores adenovirales con tropismo modificado. También se revelan composiciones que comprenden dichos vectores y métodos de uso de los mismos.
ARP070103361A 2006-07-28 2007-07-30 Metoods y composiciones para aumentar el tropismo tisular de vectores adenovirales recombinantes AR062145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83398506P 2006-07-28 2006-07-28

Publications (1)

Publication Number Publication Date
AR062145A1 true AR062145A1 (es) 2008-10-15

Family

ID=38981845

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103361A AR062145A1 (es) 2006-07-28 2007-07-30 Metoods y composiciones para aumentar el tropismo tisular de vectores adenovirales recombinantes

Country Status (12)

Country Link
US (1) US8163544B2 (es)
EP (1) EP2059602A4 (es)
JP (1) JP2009544303A (es)
KR (1) KR20090038910A (es)
CN (1) CN101849012A (es)
AR (1) AR062145A1 (es)
AU (1) AU2007278887A1 (es)
BR (1) BRPI0714932A2 (es)
CA (1) CA2658805A1 (es)
MX (1) MX2009000898A (es)
TW (1) TW200829273A (es)
WO (1) WO2008012682A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101849012A (zh) * 2006-07-28 2010-09-29 联邦科学和工业研究组织 用于增加重组腺病毒载体的组织嗜性的方法和组合物
US20100150959A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
US8865182B2 (en) * 2009-07-31 2014-10-21 Paxvax, Inc. Adenoviral-based vectors
WO2017195919A1 (ko) * 2016-05-12 2017-11-16 주식회사 바이오앱 식물 유래의 돼지 열병 백신용 조성물 및 이의 제조방법
CN107267469B (zh) * 2017-08-22 2020-06-16 广州医科大学附属第一医院 纤毛蛋白嵌合型重组人b型腺病毒及其制备方法
CN112625095B (zh) * 2021-01-13 2023-01-03 武汉科前生物股份有限公司 一种猪轮状病毒重组蛋白以及表达该蛋白的重组腺病毒和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6492343B1 (en) 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome
WO1999055365A1 (en) * 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
EP1191105A1 (en) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gene delivery vectors provided with a tissue tropism for T-lymphocytes
CA2410665C (en) 2000-05-31 2017-11-07 University Of Saskatchewan Modified bovine adenovirus having altered tropism
US20030219899A1 (en) * 2001-04-17 2003-11-27 Nikolay Korokhov Mosaic adenoviral vectors
CN101849012A (zh) * 2006-07-28 2010-09-29 联邦科学和工业研究组织 用于增加重组腺病毒载体的组织嗜性的方法和组合物

Also Published As

Publication number Publication date
KR20090038910A (ko) 2009-04-21
EP2059602A4 (en) 2010-06-23
WO2008012682A2 (en) 2008-01-31
JP2009544303A (ja) 2009-12-17
CA2658805A1 (en) 2008-01-31
WO2008012682A3 (en) 2008-06-19
EP2059602A2 (en) 2009-05-20
WO2008012682A8 (en) 2009-08-13
AU2007278887A1 (en) 2008-01-31
US8163544B2 (en) 2012-04-24
US20100104600A1 (en) 2010-04-29
CN101849012A (zh) 2010-09-29
BRPI0714932A2 (pt) 2013-05-21
MX2009000898A (es) 2009-02-04
TW200829273A (en) 2008-07-16

Similar Documents

Publication Publication Date Title
BRPI0708344B8 (pt) vetores adenovirais quiméricos e composição imunogênica
CO6630181A2 (es) Composiciones y métodos para uso de anticuerpos terapéuticos de lrp6( proteina relacionada con lipoproteínas de baja densidad 6)
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
CR20150088A (es) Anticuerpos anti-notch1 nrr
CO6491076A2 (es) Formulaciones de toxinas botulínica libre de albúmina
BRPI1008061A8 (pt) polipeptídeos recombinantes estendidos e composições compreendendo os mesmos
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CO6430468A2 (es) Anticuerpos anti-fcrh5 e inmunoconjugados y métodos de uso
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
BRPI0810863A2 (pt) Uso de hidrolisados de proteína para estabilizar formulações de detergente de metaloprotease.
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
BRPI0811871A2 (pt) Composições agroquímicas ácidas bioativas e uso das mesmas
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
BRPI0910852A2 (pt) composições contendo lipídios e métodos de uso das mesmas
CL2011000301A1 (es) Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
CL2008001879A1 (es) Compuestos derivados de isaxolinas-naftalen-carboamida; y el uso de los compuestos en el control de plagas de invertebrados en animales.
CR20110640A (es) Derivados de amiloide p sérico/de suero y su preparación y uso
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
AR062145A1 (es) Metoods y composiciones para aumentar el tropismo tisular de vectores adenovirales recombinantes
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
BRPI0606506A2 (pt) polipeptìdeos de yersinia spp. e métodos de uso
CR20110034A (es) Peptidos de señalizacion de la crkl
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
DK2173868T3 (da) Rekombinant fremstilling af udvalgte bromelainfraktioner
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure